# Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Source: https://onco.cc/trials/nct05696626/  
OnCo record `nct05696626` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Abemaciclib and Fulvestrant in advanced solid tumours, run by LeonaBio, now recruiting.

## Summary

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation is a phase 3 interventional study registered as NCT05696626 by LeonaBio, with 600 participants planned, started 2023-10-31 and due to reach its primary completion in 2027-04. Interventions recorded: Lasofoxifene in combination with abemaciclib and Fulvestrant in combination with abemaciclib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05696626
- Phase: 3
- Setting: An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Sponsor: LeonaBio
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT05696626: https://clinicaltrials.gov/study/NCT05696626

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/)

---
JSON: https://onco.cc/api/v1/entities/nct05696626.json